260
Participants
Start Date
October 20, 2025
Primary Completion Date
June 20, 2028
Study Completion Date
October 20, 2028
Ustekinumab
Ustekinumab group (induction phase with intravenous equivalent doses at weeks 0 and 8, maintenance phase with 90 mg subcutaneously every 8 weeks)
Risankizumab
Risankizumab group (induction phase with intravenous 600 mg at weeks 0, 4, and 8, maintenance phase with 360 mg subcutaneously every 8 weeks)
Taizhou Hospital
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER